| Bhcmg Executive Er | |
|
8530 Wilshire Blvd Suite 250 Beverly Hills CA 90211-3122 | |
| (310) 657-0366 | |
| (310) 657-0466 |
| Full Name | Bhcmg Executive Er |
|---|---|
| Speciality | Clinic/Center |
| Location | 8530 Wilshire Blvd, Beverly Hills, California |
| Authorized Official Name and Position | Daniel Jacobsen (PRESIDENT) |
| Authorized Official Contact | 3106570366 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Bhcmg Executive Er 8530 Wilshire Blvd Suite 250 Beverly Hills CA 90211-3122 Ph: (310) 657-0366 | Bhcmg Executive Er 8530 Wilshire Blvd Suite 250 Beverly Hills CA 90211-3122 Ph: (310) 657-0366 |
| NPI Number | 1053642009 |
|---|---|
| Provider Enumeration Date | 01/14/2010 |
| Last Update Date | 01/14/2010 |
| Medicare PECOS PAC ID | 9638207905 |
|---|---|
| Medicare Enrollment ID | O20100506000381 |
News Archive
Virginia Commonwealth University researchers have found that an inflammatory mechanism known as inflammasome may lead to more damage in the heart following injury such as a heart attack, pointing researchers toward developing more targeted strategies to block the inflammatory mechanisms involved.
An onslaught of ads targets vulnerable Democrats for their support of the overhaul. Health law opponents, notably the Americans for Prosperity group, which is in part financed by the Koch brothers, have spent an estimated $20 million on television advertising.
PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053642009 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | A85541 (California) | Primary |
| 261QM1300X | Clinic/center - Multi-specialty | DC15646 (California) | Secondary |
| Provider Name | Daniel F Jacobsen |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1629178199 PECOS PAC ID: 6204899966 Enrollment ID: I20050330000769 |
News Archive
Virginia Commonwealth University researchers have found that an inflammatory mechanism known as inflammasome may lead to more damage in the heart following injury such as a heart attack, pointing researchers toward developing more targeted strategies to block the inflammatory mechanisms involved.
An onslaught of ads targets vulnerable Democrats for their support of the overhaul. Health law opponents, notably the Americans for Prosperity group, which is in part financed by the Koch brothers, have spent an estimated $20 million on television advertising.
PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
› Verified 2 days ago
| Provider Name | Leif E Lunsford |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1740236967 PECOS PAC ID: 5890791842 Enrollment ID: I20061013000388 |
News Archive
Virginia Commonwealth University researchers have found that an inflammatory mechanism known as inflammasome may lead to more damage in the heart following injury such as a heart attack, pointing researchers toward developing more targeted strategies to block the inflammatory mechanisms involved.
An onslaught of ads targets vulnerable Democrats for their support of the overhaul. Health law opponents, notably the Americans for Prosperity group, which is in part financed by the Koch brothers, have spent an estimated $20 million on television advertising.
PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
› Verified 2 days ago
| Provider Name | Darren M Boyer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992960462 PECOS PAC ID: 8224355086 Enrollment ID: I20150317000002 |
News Archive
Virginia Commonwealth University researchers have found that an inflammatory mechanism known as inflammasome may lead to more damage in the heart following injury such as a heart attack, pointing researchers toward developing more targeted strategies to block the inflammatory mechanisms involved.
An onslaught of ads targets vulnerable Democrats for their support of the overhaul. Health law opponents, notably the Americans for Prosperity group, which is in part financed by the Koch brothers, have spent an estimated $20 million on television advertising.
PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
› Verified 2 days ago
News Archive
Virginia Commonwealth University researchers have found that an inflammatory mechanism known as inflammasome may lead to more damage in the heart following injury such as a heart attack, pointing researchers toward developing more targeted strategies to block the inflammatory mechanisms involved.
An onslaught of ads targets vulnerable Democrats for their support of the overhaul. Health law opponents, notably the Americans for Prosperity group, which is in part financed by the Koch brothers, have spent an estimated $20 million on television advertising.
PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
› Verified 2 days ago
Treatmedngo Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8950 W Olympic Blvd Ste 103&104, Beverly Hills, CA 90211 Phone: 310-274-8080 | |
Refael Medical, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8200 Wilshire Blvd, Beverly Hills, CA 90211 Phone: 310-879-7167 Fax: 310-933-5688 | |
Michael D. Borookhim, M.d., Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9301 Wilshire Blvd, Suite 602, Beverly Hills, CA 90210 Phone: 310-288-0881 | |
Ultrasound Specialists Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9001 Wilshire Blvd, Suite 106, Beverly Hills, CA 90211 Phone: 310-273-8885 | |
Kaiser Permanente Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 204 S Arnaz Dr Apt 3, Beverly Hills, CA 90211 Phone: 213-215-5142 | |
Nancy P. Rahnama, M.d., A.p.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 421 N Rodeo Dr, Penthouse Number 1, Beverly Hills, CA 90210 Phone: 310-299-7373 Fax: 310-432-6647 | |
Laurence Seigler, M.d. Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 435 N Bedford Dr, Suite 308, Beverly Hills, CA 90210 Phone: 310-274-6158 Fax: 310-274-5709 |